Dana Blankenhorn

Rethinking Healthcare

The second Tylenol crisis is on

By Dana Blankenhorn | Jan 15, 2010 |

I last wrote about Tylenol here six months ago.

Back then the issue was that people were taking too much of it. Now the company has had to recall a lot of Tylenol, and related products, because wooden pallets used for packaging materials contained a chemical that broke down into 2,4,6-tribromoanisole (TBA).

TBA is a well known hazard in the wine industry. It can turn even good wine musty, or “off.” Yet wine-makers have to maintain humid cellars for the wine to age properly. You want to sell no wine before its time, but if TBA gets into your cellar it’s too late.

TBA is also a hazard in the packaged foods business. There’s a fungus that can turn a well-known fungicide into nasty-smelling TBA. Put grapes in plastic pouches and they can be ruined within a week, just from being near tainted fiberboard.

With the lessons of its 1982 scandal, caused by someone deliberately poisoning capsules on store shelves, firmly in mind.  the company has once more moved aggressively.

It has produced a Web site, McNeilproductrecall, listing lots of six different products that may be affected, issuing a soothing press release saying they’re getting to the bottom of the pallet issue and recalling anything that may be suspected of taint.

Your nose will know if your medicine has a problem. Consumers have reported a “moldy, musty or mildew-like odor” since December.

A writer at Gather.com asks if this is becoming an annual problem. Tylenol recalled some liquid products last year, it was mixed with narcotics in products like Vicodin, and the FDA last year recommended lower dosages.

The Gather.com comment, however, gets to the real heart of the problem. Fool me once, shame on you and fool me twice, shame on me. What about fool me four or five times?

At the heart of J&J’s success in 1982 was that it took responsibility quickly, not for something it did but for something a third party did, and that it immediately took expensive steps not only to get its product off the shelves (it had a 37% share of the pain reliever market) but to keep it from happening again.

In this case, there’s no doubt the company is responsible. This is also involving more products than just Tylenol, which could add a taint to the company’s reputation for some time.

This will cost J&J more money than the 1982 scare, and result in damage that is harder to fix.

 

Smartplanet TalkbackShare your ideas and expertise on this topic

The following tags are supported in Smartplanet comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. Name: You are currently: a Guest |
advertisement

Quick Poll

advertisement

Dana Blankenhorn

Dana Blankenhorn has been a business journalist for nearly 25 years and has covered the online world professionally since 1985. He founded the Interactive Age Daily for CMP Media, and has written for the Chicago Tribune, Advertising Age's "NetMarketing" supplement, and dozens of other publications over the years.

Dana Blankenhorn

Dana Blankenhorn has been a technology reporter since 1982, a business reporter since 1978, and a writer for as long as he can remember. His Schwab IRA has a few tech stocks in it, most notably some Intel and Applied Materials bought over 10 years ago. But the vast majority of his tiny fortune (emphasis on the word tiny) is invested in mutual funds. He presently writes for no one else but ZDNet, SmartPlanet and himself. But if you've got an opportunity let him know. If he takes the gig he"ll first add it to this disclosure page.
Rethinking Healthcare examines innovation in the health care industry covering topics such as electronic and personal health records, treatment, privacy, regulation and using information technology to manage and monitor chronic conditions.